Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · IEX Real-Time Price · USD
12.29
+0.12 (0.99%)
At close: Jul 19, 2024, 4:00 PM
12.30
+0.01 (0.08%)
Pre-market: Jul 22, 2024, 7:08 AM EDT
Sage Therapeutics Revenue
Sage Therapeutics had revenue of $91.06M in the twelve months ending March 31, 2024, with 868.87% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $7.90M with 139.89% year-over-year growth. In the year 2023, Sage Therapeutics had annual revenue of $86.46M with 1,024.84% growth.
Revenue (ttm)
$91.06M
Revenue Growth
+868.87%
P/S Ratio
8.12
Revenue / Employee
$186,990
Employees
487
Market Cap
739.64M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86.46M | 78.77M | 1,024.84% |
Dec 31, 2022 | 7.69M | 1.38M | 21.85% |
Dec 31, 2021 | 6.31M | -1.11B | -99.43% |
Dec 31, 2020 | 1.11B | 1.11B | 16,123.06% |
Dec 31, 2019 | 6.87M | -83.41M | -92.39% |
Dec 31, 2018 | 90.27M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Evolus | 219.70M |
Travere Therapeutics | 183.23M |
Wave Life Sciences | 112.91M |
4D Molecular Therapeutics | 20.45M |
Stoke Therapeutics | 7.85M |
Lexicon Pharmaceuticals | 2.31M |
Pliant Therapeutics | 248.00K |
SAGE News
- 2 days ago - Sage Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Investors With Losses Are Urged To Start Dialogues - Accesswire
- 3 days ago - The Schall Law Firm Is Investigating Sage Therapeutics Inc For Potential Securities Breaches And Encourages Investors Who Have Experienced Losses To Initiate Dialogues - Accesswire
- 4 days ago - Sage Therapeutics Inc Is Under Examination For Possible Securities Violations By The Schall Law Firm, Investors Who Have Suffered Losses Are Urged To Begin Conversations - Accesswire
- 5 days ago - Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 - Business Wire
- 5 days ago - The Schall Law Firm Encourages Investors With Losses To Initiate Dialogue, Sage Therapeutics Inc Is Under Scrutiny For Potential Securities Violations - Accesswire
- 6 days ago - Sage Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Breaches Urging Investors With Losses To Start Conversation - Accesswire
- 8 days ago - The Schall Law Firm Begins Investigation Into Sage Therapeutics Inc For Potential Securities Violations And Urges Investors With Losses To Initiate Conversation - Accesswire
- 9 days ago - Inquiry Into Sage Therapeutics Inc For Possible Securities Breaches Initiated By The Schall Law Firm Encouraging Investors With Losses To Start Dialogue - Accesswire